Compare ENLV & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENLV | FT |
|---|---|---|
| Founded | 2005 | 1988 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 199.8M |
| IPO Year | 2014 | N/A |
| Metric | ENLV | FT |
|---|---|---|
| Price | $0.67 | $7.99 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 409.3K | 40.1K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $7.43 |
| 52 Week High | $2.10 | $8.35 |
| Indicator | ENLV | FT |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 47.57 |
| Support Level | $0.66 | $7.83 |
| Resistance Level | $1.23 | $8.05 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.44 | 58.33 |
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.